Delta Global Management LP Buys New Holdings in DaVita Inc. $DVA

Delta Global Management LP purchased a new position in DaVita Inc. (NYSE:DVA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,871 shares of the company’s stock, valued at approximately $1,710,000.

Several other institutional investors and hedge funds have also recently modified their holdings of DVA. MAI Capital Management boosted its position in shares of DaVita by 23.4% during the second quarter. MAI Capital Management now owns 438 shares of the company’s stock worth $62,000 after acquiring an additional 83 shares during the last quarter. NewEdge Advisors LLC increased its holdings in DaVita by 20.8% in the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company’s stock valued at $78,000 after acquiring an additional 88 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in DaVita by 34.9% in the 3rd quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock worth $59,000 after purchasing an additional 117 shares in the last quarter. Bank of Nova Scotia lifted its stake in DaVita by 2.5% in the 3rd quarter. Bank of Nova Scotia now owns 4,933 shares of the company’s stock worth $655,000 after purchasing an additional 120 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of DaVita by 1.2% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 10,184 shares of the company’s stock valued at $1,451,000 after purchasing an additional 122 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Trading Down 1.7%

DVA opened at $148.08 on Tuesday. The stock has a 50-day moving average of $132.49 and a 200 day moving average of $127.10. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $159.42. The firm has a market cap of $9.89 billion, a P/E ratio of 14.94, a P/E/G ratio of 0.53 and a beta of 0.93.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Monday, February 2nd. The company reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.24 by $0.16. The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The company’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on DVA shares. Truist Financial set a $158.00 target price on DaVita in a report on Thursday, February 5th. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. UBS Group raised their price target on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Barclays upped their price objective on DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 3rd. Finally, Zacks Research upgraded DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $155.80.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.